



# Effects of sex and estrous cycle on sleep and cataplexy in narcoleptic mice

Sébastien Arthaud, Manon Villalba, Camille Blondet, Anne-Laure Morel,  
Christelle Peyron

## ► To cite this version:

Sébastien Arthaud, Manon Villalba, Camille Blondet, Anne-Laure Morel, Christelle Peyron. Effects of sex and estrous cycle on sleep and cataplexy in narcoleptic mice. *SLEEP*, 2022, 45 (7), 10.1093/sleep/zsac089 . hal-03748304

**HAL Id: hal-03748304**

**<https://hal.science/hal-03748304>**

Submitted on 17 Aug 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Title Page

### Effects of sex and estrous cycle on sleep and cataplexy in narcoleptic mice

Sébastien Arthaud<sup>1,2,a</sup>, Manon Villalba<sup>1,2,a</sup>, Camille Blondet<sup>2</sup>, Anne-Laure Morel<sup>1,2</sup>, Christelle Peyron<sup>\*1,2</sup>

<sup>1</sup> Center for Research in Neuroscience of Lyon (CRNL), SLEEP team, CNRS UMR5292, INSERM U1028, Centre Hospitalier le Vinatier – Bâtiment 462 – Neurocampus Michel Juvet, 95 boulevard Pinel, 69675 Bron Cedex, France

<sup>2</sup> University Lyon1, Lyon, France

<sup>a</sup> Equal contribution

\*Corresponding author: Dr. Christelle Peyron, PhD

CRNL, SLEEP team, CNRS UMR5292, INSERM U1028, Centre Hospitalier le Vinatier – Bâtiment 462 – Neurocampus Michel Juvet, 95 boulevard Pinel, 69675 Bron Cedex, France; Email : [peyron@sommeil.univ-lyon1.fr](mailto:peyron@sommeil.univ-lyon1.fr)

## **Abstract**

Narcolepsy type 1 (NT1) is a rare neurology disorder caused by the loss of orexin/hypocretin neurons. NT1 is characterized by excessive daytime sleepiness, sleep and wake fragmentation and cataplexy. These symptoms have been equally described in both women and men, although influences of gender and hormonal cycles have been poorly studied. Unfortunately, most studies with NT1 pre-clinical mouse models, use only male mice to limit potential variations due to the hormonal cycle. Therefore, whether gender and/or hormonal cycles impact the expression of narcoleptic symptoms remains to be determined. To address this question, we analyzed vigilance states and cataplexy in 20 female and 17 male adult orexin knock-out narcoleptic mice, with half of the females being recorded over multiple days. Mice had access to chocolate to encourage the occurrence of cataplectic episodes. A vaginal smear was performed daily in female mice to establish the state of the estrous cycle of the previous recorded night. We found that vigilance states were more fragmented in males than females, that females had less paradoxical sleep ( $p=0.0315$ ) but more cataplexy ( $p=0.0375$ ). Interestingly, sleep and wake features were unchanged across the female estrous cycle, but the total amount of cataplexy was doubled during estrus compared to other stages of the cycle ( $p=0.001$ ), due to a large increase in the number of cataplexy episodes ( $p=0.0002$ ). Altogether these data highlight sex differences in the expression of narcolepsy symptoms in orexin knock-out mice. Notably, cataplexy occurrence was greatly influenced by estrous cycle. Whether it is due to hormonal changes would need to be further explored.

## **Keywords**

narcolepsy, hormone, hypothalamus, REM sleep, female, neuroendocrine

**Significance statement**

This study provides evidence that sex and the estrous cycle influence cataplexy severity in a preclinical mouse model of narcolepsy type 1. Of particular interest, it shows for the first time that the amount of cataplexy is doubled during the estrus stage in female orexin-deficient mice. Gender differences in narcolepsy type 1 is largely overlooked and studies on the influence of the menstrual cycle on the severity of symptoms are largely absent. Future studies evaluating the influence of gender and hormonal fluctuations on symptom severity of narcolepsy would be of great interest to the benefit of patients and to get a better understanding of the disease.

## INTRODUCTION

Female-male differences are common at the cellular level and can arise from many factors such as sex-chromosome gene expression, specializations in receptors expression or levels of circulating hormones. In turn, these cell-based sex differences can give rise to female-male differences in brain networks and behaviors. Such effects may have substantial implications in sleep regulation and sleep disorders, some showing a clear difference in men-women prevalence. Accordingly, sex differences in sleep amount, sleep architecture, slow gamma power or sleep spindle characteristics have been reported [1–4]. Hormonal fluctuations over the estrous or menstrual cycle also induce variations on sleep architecture [1,4–8].

Narcolepsy type 1 (NT1) is an orphan neurological disorder that is characterized by excessive daytime sleepiness, paradoxical sleep (PS, as called REM sleep) dysregulation, hypnagogic hallucinations, sleep paralysis and episodes of cataplexy [9]. A few studies have evaluated men-women prevalence of NT1 but some showed no major gender effect [10], a slight predominance for men [11] or a higher incidence in women [12,13].

The etiology of NT1 is caused by the specific postnatal loss of orexin/hypocretin (OREX) neurons of the lateral hypothalamus [14,15]. Cataplexy - a pathognomonic symptom of NT1 depicted by a bilateral loss of postural muscle tone during wakefulness and triggered by a strong, generally positive emotion without loss of consciousness [16,17] - is strongly associated with the loss of OREX [18–22]. Interestingly, a few studies have shown that preprohypocretin mRNA and OREX-A protein levels in lateral hypothalamus and the cerebrospinal fluid are higher in female rats compared to males [23–25]. Additionally, it has been reported that sex hormone fluctuations across the estrous cycle (EC) affect OREX expression [26,27].

In light of these data, it can be hypothesized that the loss of OREX may have a different impact on females vs. males with a potential gender difference in symptom severity in NT1 such as sleepiness, PS dysregulation and/or cataplexy.

Of particular interest, the severity of cataplexy - in its frequency and extent - varies greatly among patients [28]. Gender differences have been largely understudied with no consensus between studies [10,29–31] and, to our knowledge, the impact of the menstrual cycle has not yet been evaluated. Similarly, except for the most recent studies [32–34], only male mice were classically included in pre-clinical studies on narcolepsy. To fill this gap in our knowledge, two recent studies [35,36] investigated sex-related differences on sleep in an inducible mouse model of narcolepsy and reported no difference for sleep and wake amounts. Coffey et al [35] additionally found that female experienced more cataplexy than males. However, none of those studies evaluated whether EC influences the expression of cataplexy.

Here, we first evaluated whether sex influences sleep-wake features and cataplexy in a well-established mouse model of narcolepsy, the OREX Knock-Out mice (Orex-KO). Secondly, we quantified sleep, wake and cataplexy across the EC of these mice.

## METHODS

**Animals.** Experiments were conducted with a mouse model of NT1 exhibiting sleep fragmentation and cataplexy, the Orex-KO mice [18] of C57Bl/6J genetic background. Twenty nulliparous female and 17 male mice were implanted for polysomnography recordings at 12 weeks of age ( $23.2 \pm 0.5$  g and  $28.6 \pm 0.8$  g respectively;  $p < 0.0001$ ). Mice were recorded between 13 and 17 weeks of age, some being recorded for several weeks, across several estrous cycles. Animals were maintained under constant light/dark cycle (12:12 hours, lights on at 07:00 AM) with *ad libitum* access to water and regular chow throughout the experiment. Room temperature was kept at  $23 \pm 1^\circ\text{C}$ . The experimental procedures were approved by the CELYNE Ethics Research Committee (protocol #21759) in accordance with the European Community guidelines for care in animal research.

**Experimental design.** Seven to 10 days after surgery, mice were individually hosted in transparent Plexiglas barrels (30cm in diameter) placed in an open-space recording chamber containing 4 barrels. Mice were able to see, hear and smell but not touch each other. Barrels were enriched with a running wheel (diameter: 15.5cm) and paper cuttings for nest building to improve animal welfare [37–39]. After 3 days of habituation to this new environment, mice were recorded continuously.

In a first set of experiments, Orex-KO mice - 10 females and 9 males - were recorded in groups of up to 4 mice of the same sex. They were first recorded in baseline conditions for 24hrs. The following day, a piece of milk chocolate was given to each mouse at 6:30 PM in addition to regular food to encourage the occurrence of cataplexy [38]. Note that among the 10 female mice, 8 were recorded in both baseline and chocolate conditions, 1 was only recorded in baseline condition and 1 was recorded under chocolate treatment only. The latter two females were integrated into the analyses but only when unpaired comparisons were made. All males were recorded in baseline and under chocolate conditions.

In a second set of experiments, 4 series of 2-3 females and 1 male were recorded for several nights in a row to obtain multiple recordings per EC stage. The presence of a male in the chamber encouraged

female estrus and reduced any anestrus. To determine the stage of the EC of the previous night, a vaginal smear was performed by a trained experimenter each morning between 9:00 and 10:00 AM. For each 12hrs of night of recording, one male was analyzed in parallel with the females to uncover potential effects due to their presence. Note that one night of baseline was recorded, then chocolate was added on each of the following recorded nights. Unfortunately, for two of these 10 females and one of the 4 males, recordings were not available without chocolate. Furthermore, to evaluate whether the presence of females would affect sleep and cataplexy in males, 4 additional males were recorded in presence of 3 females (for a total of 8 males). Note that these females were not recorded but their EC was evaluated.

**Surgical procedure.** Anesthesia was induced by an intraperitoneal injection of a cocktail of ketamine: xylazine (100 : 10 mg/kg) then mice were placed on a stereotaxic frame (David Kopf Instruments, USA) where they were implanted with three electroencephalogram (EEG) electrodes: one above the parietal cortex (1.5mm lateral to midline and -2.5mm posterior to Bregma) and one above the frontal cortex (1mm lateral to midline and 1.5mm anterior to Bregma), the last one above the cerebellum (1.5mm lateral to midline and 7mm posterior to Bregma) to be used as reference. Two electromyogram (EMG) electrodes were slipped between neck muscles. Then, all EEG and EMG electrodes were connected to a miniature plug (Plastics One, Bilaney, Germany), fixed to the skull using acrylic cement (Superbond, C&B Sun Medical) and further coated using dental cement (Paladur, Heraeus Kulzer). A subcutaneous injection of carprofen (5 mg/kg) was administered at the end of surgery for pain caring.

**Polysomnographic recordings.** Mice were connected to a cable plugged to a rotating connector (Bilaney, Plastics One, Germany) to allow free movements during recordings and were acclimated to the recording chamber and EEG/EMG cable for at least 3 days. Each frontal and parietal EEG signal was referenced to the cerebellar EEG electrode, and muscle tone was assessed by a differential EMG signal [40]. Briefly, EEG and EMG signals were amplified (EEG: 2000x; EMG: 5000x; A-M systems, Model 3500, Sequim, WA 98382, US), filtered (bandwidth 1-100 Hz for the EEG, 10-100 Hz for the EMG), digitized



(NI Usb 6343 card, National Instrument, Austin, US, sampling rate 1024 Hz) and collected using Sleepscore software (Viewpoint, Lyon, France). Video recordings were continuously collected with an infra-red camera fixed above each barrel (Point Grey firefly MV, Black & White, 640x480, 15 frames/sec).

**Quantification of the vigilance states and cataplexy.** Vigilance states were scored using a 5 sec window frame according to standard criteria using Sleepscore [40]. Wake (WK), slow-wave sleep (SWS) and PS were assigned using the standard mouse EEG/EMG scoring method, based on rules established in wild-type mice [41]. Cataplexy was identified according to the consensual definition [42] using both EEG/EMG and simultaneous video recordings [43] and the four following criteria (1) an abrupt episode of nuchal muscle atonia lasting for at least 10 sec, (2) with immobility of the animal during the entire episode, (3) an EEG signal rich in theta and low in delta activities, and (4) at least 40 sec of WK prior to the episode (supplementary Video). In addition, attacks were considered as cataplexy when occurring outside the nest, during a period of high motor activity [39].

**Estrous cycle staging.** Mouse EC is classically divided into 4 stages: proestrus (P), estrus (E), metestrus (M) and diestrus (D) using vaginal cytology, a cycle that repeats it-self every 4-5 days unless interrupted by pregnancy or anestrus [44]. A vaginal lavage was performed daily between 09:00 and 10:00 AM to collect vaginal cells as previously described [45]. The smear was air-dried at room temperature, stained using crystal violet (Sigma Aldrich) for 1 minute, gently washed twice in distilled water and coverslipped with glycerol (Sigma Aldrich). The observation was performed under a light microscope immediately after staining. Each EC stage was identified according to its relative ratio of polymorphonuclear leukocytes, cornified squamous epithelial cells and nucleated epithelial cells [1,44,45]. P was defined by the predominance of nucleated epithelial cells accompanied by a few cornified epithelial cells (Figure S1A). E was determined when cornified epithelial cells were mostly present (Figure S1B). In M, cornified epithelial cells and leukocytes were present while nucleated cells were absent (Figure S1C). In D, leukocytes were predominant but epithelial cells were also found (Figure S1D).

**Photomicrographs.** They were taken using an Axioskop microscope (Axioskop 2 plus, Zeiss) and a color video camera (ProgRes CF, Jenoptik) connected to an imaging analysis system (MorphoLight, ExploraNova, France).

**Statistical analysis.** Graphs and statistical analyses were performed using GraphPad Prism (v9) and significance set at 0.05.

To compare females to males, since mice were recorded for several nights in a row, we first calculated sleep/wake and cataplexy median values of the repeated recordings for each mouse regardless of the EC. Normality of distribution was assessed using Shapiro-Wilk test. Unpaired t-test was performed on data with normal distributions while non-parametric Mann-Whitney test was applied when the normality assumption was violated. When comparing females or males in baseline vs. chocolate, we performed Wilcoxon or paired t-tests depending on normality of the data distribution. Weight difference between groups was evaluated using an unpaired t-test and relations between weight and the occurrence of cataplexy were verified by using a Pearson correlation test.

To analyze vigilance states and cataplexy across EC, a repeated-measures analysis of variance (ANOVA) with one dimension (EC stages) was performed, followed by a post-hoc Tukey's test for multiple comparisons when appropriate. To limit any masking effects due to the previously described high intra- and inter-individual variability in cataplexy occurrence (Figure S2) [39,46], data were normalized. For each parameter studied and each female mouse, we first determined a reference value, the median of each EC stage median value. Then each measure was normalized by calculating the ratio of the value to its reference. We were thus able to evaluate the expression of cataplexy according to the different stages of the EC and compare mice with each other. We used a similar strategy to normalize the amount of cataplexy in males recorded in the presence of 0, 1, 2 or 3 females with concomitant E.

The data underlying this article will be shared on reasonable request to the corresponding author.

## RESULTS

### INFLUENCE OF SEX ON VIGILANCE STATES

To evaluate whether sex could influence sleep and wake features and cataplexy in Orex-KO mice, females and males recorded in absence of the opposite sex were first compared in baseline condition then under chocolate stimulation.

Nine female and nine male mice were first compared in terms of WK, SWS and PS quantity, number of episodes and mean episode duration over 24 hrs. Female mice had the same amount of WK and SWS with a similar level of fragmentation than males (Table 1), but had less PS ( $p=0.0315$ ) due to a highly reduced number of PS bouts ( $p=0.0025$ ) (Table 1). During the light phase, only the number of PS episodes was mildly reduced in females compared to males ( $p=0.0448$ ) (Table S1). However, during the dark phase, all vigilance states - WK, SWS and PS - were more fragmented in males than females with a higher number of bouts of shorter mean durations (Figure 1; Table S2). Accordingly, PS latency was significantly shorter in males than females ( $4.81\pm1.5$  vs.  $28.80\pm7.2$  min, respectively; unpaired t-test  $p=0.0050$ ).

With the aim of combining females and males in future studies and recording them in parallel in an open-space, we evaluated whether the presence of mice of the opposite sex would influence vigilance states in Orex-KO mice during the dark phase. We found no significant differences between females recorded in the presence or absence of males for all parameters studied (total amount, number of episodes and mean episode durations) of WK, SWS and PS (Figure 1; Table S2). Similarly, the presence of females did not alter vigilance states in males (Figure 1; Table S2). When comparing animals recorded in the presence of a member of the opposite sex, we found no female-male differences for WK, SWS and PS (Figure 1; Table S2).

In most studies, chocolate is given to mice just before light-off to favor the occurrence of cataplexy. We thus evaluated whether chocolate would influence vigilance states during the dark phase and whether it would do it in a similar proportion in both females and males.

Chocolate treatment increased WK, decreased SWS and had no significant effect on PS in female and male Orex-KO mice compared to their respective baseline (paired t-tests; Table 2). However, these chocolate effects tended to be of different amplitudes in females vs males (Table 2). In particular, females showed a nearly 50% reduction in SWS ( $p=0.0012$ ) while males had an only a 28% reduction ( $p=0.0115$ ). In both males and females, the SWS mean episode duration was reduced but females also had less SWS bouts while having access to chocolate, than during baseline ( $p=0.0038$ ) (Table 2). As a result, females were slightly more awake ( $p=0.0464$ ) and had significantly less SWS ( $p=0.0135$ ) than males under chocolate treatment (Table 2). Furthermore, vigilance states were less fragmented in females than males with a lower number of episodes (unpaired t-tests; Table 2). However, when animals were recorded with mice of the opposite sex and with chocolate, no female-male difference was found in the amount of WK ( $p=0.46$ ), SWS ( $p=0.97$ ) or PS ( $p=0.09$ ), nor in their fragmentation index as evaluated by the number of bouts and their mean bout durations (Figure 2).

Altogether, these data showed that chocolate treatment strongly modulates vigilance states in Orex-KO mice while the presence of animals of the opposite sex has no influence.

### **EFFECTS OF SEX ON CATAPLEXY**

Cataplexy occurs essentially during the dark phase (Figure 1) and only rarely during the light phase at light-on/light-off transitions (Table S1). We thus focused on the dark phase. We found that the total amount of cataplexy in baseline condition was higher in females than male Orex-KO mice ( $p=0.0375$ ) due to a longer mean episode duration ( $p=0.0188$ ) (Figure 1J-L; Table S2). The number of cataplexy episodes tended to be higher in females than males, but it did not reach significance due to high inter-individual variability ( $p=0.08$ ) (Figures 1K and S2).

We used chocolate to encourage the occurrence of cataplexy in Orex-KO mice. Accordingly, we found a large increase in the total amount and the number of cataplexy episodes in females ( $p=0.0001$  and  $p=0.0003$ , respectively) and males ( $p=0.0039$  for both), although the increase was larger in males than females (929% vs. 378%, respectively) (Table 2). As a result, the female-male differences in the amount

of cataplexy that we observed in baseline condition (Figure 1J-L), were less prominent under chocolate treatment, although still significant ( $p=0.0294$ ) (Table 2).

As female mice were leaner than males ( $p<0.0001$ ), we verified whether the higher amount of cataplexy in females could be due to weight differences. We found no correlation between weight and the total amount of cataplexy, the number of episodes or mean episode durations of cataplexy within each group (females or males), whether we considered baseline (data not shown) or chocolate treatment (Figure S3) conditions, indicating that the amount of cataplexy was influenced by sex but not weight.

The presence of an animal of the opposite sex in the environment had no effect on the total amount of cataplexy, the number of episode or their mean duration in female or male mice compared to their baseline (Figure 1J-L; Table S2). However, when mice were recorded in the presence of the opposite sex and under chocolate treatment, the amount of cataplexy and the mean episode duration were significantly higher in females compared to males ( $p=0.0434$  and  $p=0.0404$ ) (Figure 2J and L), as in baseline (Figure 1J and L) and under chocolate (Table 2) conditions.

Altogether these results indicated that females had less fragmented sleep and WK during the dark phase but had more cataplexy than males in baseline or after chocolate treatment whether an animal of the opposite sex was present in the environment or not. Therefore, in order to determine whether the increased cataplexy was a constant or limited to a specific stage of the EC, we next quantified SWS, PS, WK and cataplexy across the female EC, attributing an EC stage to each recorded night by performing a vaginal smear on the following morning.

## **EFFECTS OF THE ESTROUS CYCLE ON VIGILANCE STATES AND CATAPLEXY OF OREX-KO FEMALE MICE**

### **Vigilance states were not modulated in females across the EC.**

We found no significant differences in the amount of time spent in WK ( $p=0.1440$ ), SWS ( $p=0.0976$ ) or PS ( $p=0.9054$ ) between P, E, M and D (Figure S4 A, D and G). Equally, we found no significant differences in the number of WK ( $p=0.2709$ ), SWS ( $p=0.1286$ ) and PS ( $p=0.7954$ ) episodes (Figure S4 B, E and

H) between EC stages nor in their mean durations (WK,  $p=0.1032$ ; SWS,  $p=0.0996$ ; PS,  $p=0.4778$ ) (Figure S4 C, F and I). Altogether, these data indicate that the EC did not modulate vigilance states in Orex-KO female mice.

#### **The occurrence of cataplexy in females was increased during the E stage.**

As previously described, we found a large intra- and inter-individual variability in the total amount and number of cataplexy episodes (Figure S2). Furthermore, due to differences in the duration of EC stages, the number of recorded nights obtained for each EC stage varied. Accordingly, cataplexy data were normalized (see methods for details). We found that the total amount of cataplexy was strongly modulated across the EC ( $p=0.001$ ) (Figure 3 A-B). It was doubled during E compared to the other EC stages (E:  $1.76\pm0.2$  vs. P:  $0.92\pm0.1$ ;  $p=0.03$ ; vs. M:  $0.81\pm0.2$ ;  $p=0.0428$ ; vs. D:  $0.81\pm0.1$ ;  $p=0.0435$ ) while it was not different between any other EC stage (P vs. M:  $p=0.9597$ ; P vs. D:  $p=0.9432$ ; M vs. D:  $p>0.9999$ ).

Similarly, the number of cataplexy episodes was also modulated across the EC ( $p=0.0002$ ), and doubled during E compared to the other EC stages (E:  $1.46\pm0.1$  vs. P:  $0.78\pm0.1$ ;  $p=0.0285$ ; vs. M:  $0.66\pm0.1$ ;  $p=0.0335$ ; vs. D:  $0.82\pm0.1$ ;  $p=0.0261$ ) and not different between other EC stages (P vs. M:  $p=0.8860$ ; P vs. D:  $p=0.9937$ ; M vs. D:  $p=0.7948$ ) (Figure 3 C-D). However, the mean cataplexy episode duration was not modulated by the EC ( $p=0.8511$ ) (Figure 3 E-F).

#### **Effect of EC on sleep and cataplexy in males.**

As described above, the presence of an animal of the opposite sex in the environment had no effect on vigilance states of female and male mice (Figure 1) and we found that vigilance states were not influenced by the EC in females (Figure S4). Accordingly, we found no difference between males and females at any of the 4 estrous states for WK, SWS and PS, with the exception of a slight significant reduction in SWS mean episode duration in males compared to females in M (Figure S4).

Interestingly, a significant increase in the total amount of cataplexy was observed between females in E and males ( $p=0.0062$ ) but not between males and females in other EC stages (Figure 3A). A similar

observation was made for the number of cataplexy episodes ( $p=0.0112$ ) (Figure 3C) and the mean episode duration ( $p=0.0193$ ) (Figure 3E), indicating that the larger amount of cataplexy in females compared to males was attributable to the E stage. It is interesting to note that those males were recorded multiple times with up to 3 females in their environment. Whether one, two, three or none of the females were in E stage (the ovulation period) had no influence on cataplexy, in terms of total duration or number of episodes (Figure S5).

## DISCUSSION

With this study we show that vigilance states are more fragmented in males and that cataplexy is prominent in females. Altogether, our data highlight sex differences in the expression of narcolepsy symptoms in Orex-KO mice. We also illustrate the high intra and inter-individual variability of cataplexy in females and males and show for the first time that cataplexy is modulated across the EC, the occurrence of cataplexy being doubled during E compared to all other EC stages.

### Effects of sex and EC on vigilance states in Orex-KO mice

Only a few sleep studies have explored sex differences in mice. It was reported that C57Bl6/J female mice had less SWS during the dark phase than males, but similar PS architecture [3]. Here, we found no female-male differences in the amount of WK, SWS and PS during the dark period of C57Bl6/J Orex-KO mice but vigilance states were more fragmented in males. Vigilance state fragmentation as well as shorter PS latency are well-documented features of narcolepsy in mice [18,46,47]. It may thus reflect symptom severity.

A recent study looking at sex differences in another mouse model of narcolepsy, the C57Bl6/J DTA narcoleptic mice, reported no differences in WK and sleep quantities between males and females except for a tendency for males to spend more time in PS than females [35]. Similarly, in our study we found higher amounts of PS with a larger number of PS episodes over 24hrs in males, an observation that was only significant for the number of PS episodes during the dark phase. Of interest, these two murine models of narcolepsy differ by the fact that only OREX is genetically deleted in the Orex-KO mice while OREX neurons are killed in narcoleptic DTA mice. OREX neurons express other neurotransmitters in addition to OREX such as dynorphin, glutamate or galanin [48], suggesting that these latter neuropeptides might only mildly intervene in the sleep phenotype. In agreement with the similarity of these two mouse models, a recent study [49] has demonstrated that OREX neuropeptide is essential for the maintenance of neuronal electrophysiological properties. OREX neurons without OREX



neuropeptides have lower spontaneous firing frequencies, lower input resistances, and a hyperpolarized membrane potential, suggesting that these neurons are less excitable and function poorly in the absence of OREX neuropeptides. The study also showed that OREX neuropeptides are responsible for the major effect on the maintenance of WK and the inhibition of PS.

Interestingly, several studies have reported that female patients display increased daytime sleepiness compared to men, as well as shorter sleep latencies on the multiple sleep latency test [10,29,31]. We found however that PS latency in males was greatly shortened compared to their female counterparts. We evaluated PS latency as the length of time between light-on and the first PS bout. The discrepancies might be due to species-related differences or to the difficulty in evaluating sleep latencies in mice where vigilance states are naturally more highly fragmented.

Healthy women tend to report a decreased quality of sleep during their menstruations and at the beginning of the follicular phase (corresponding to P+E in mice EC) [8,50]. Objective measures using polysomnography or actigraphy, reported no menstrual cycle variability in sleep [8,50,51] or slight changes with increased WK and decreased PS during the luteal phase (M+D in mice) compared to the follicular phase [5,6,8,52]. To our knowledge, it has not been evaluated in NT1 patients.

Hormonal fluctuations across EC have more or less influences on sleep architecture depending on the species of rodents [3,4,7]. These changes have been attributed to the progesterone and estradiol reproductive hormones [53] but only partially since, although they disappear in ovariectomized females, they are only partially recovered by hormonal supplementation [3,54]. According to Koehl et al [7] genotypes seemed to have a stronger effect on sleep than sex hormones. In rats, females were more alert at the expense of sleep and in particular of PS during P, when ovulation occurs [4,53,55] followed by a SWS and PS rebound during E [4]. The EC seems to have limited effects on sleep and WK in wild-type female mice of C57Bl6/J genotype, with a slight PS reduction in P compared to D during the dark period and no difference with the other EC stages [7]. Similarly, we found no modulation for all sleep and WK features studied across the EC in C57Bl6/J Orex-KO narcoleptic female mice. It is important to

note however that shorter ECs in mice might preclude the uncovering of mild hormonal influences on sleep.

### **Effects of sex and EC on cataplexy in mice**

We found that females Orex-KO mice had more cataplexy than males. Similarly, female narcoleptic dogs showed more severe cataplexy attacks than males [56], DTA narcoleptic female mice exhibited earlier occurrence of cataplexy than males when NT1 was developing [36] and showed more cataplexy than males when the disease had settled [35]. Taken altogether, animal models of NT1 suggest that the severity of cataplexy would be elevated in females compared to males. Gender differences in the severity of cataplexy has rarely been evaluated and results are quite controversial, probably due to the limited number of patients included in these studies. Indeed, Luca et al [10] reported no differences while Mattarozzi et al [30] found a larger proportion of men with a higher frequency of cataplexy than women and Won et al [31] declared that women reported more occurrences of cataplexy than men. Further studies are thus needed to clarify whether gender might influence the severity of cataplexy in human NT1 patients.

We show here, for the first time, that cataplexy is influenced by the EC in Orex-KO narcoleptic mice with cataplexy occurring twice more frequently during the E stage compared to the other EC stages. This effect is due to a higher number of bouts during E. Although we found that the amount of cataplexy generally correlates with time spent in WK (data not shown), we found that a similar amount of WK during E compared to the other EC stages. It thus does not explain the increased number of cataplexy episodes during E. In mice, a peak in follicle-stimulating hormone levels and a small surge in prolactin signal ovulation and entry into E. During E, 17- $\beta$ -estradiol levels decline while progesterone levels are low and prolactin levels peak [45]. Whether and how sex hormones or prolactin levels would influence cataplexy expression is unknown and ought to be explored. Similarly, to our knowledge, severity of cataplexy in patients has not been evaluated regarding the menstrual cycle, it needs to be explored.

## Technical considerations

We focused most of our observations on the dark phase because the main symptoms of narcolepsy (sleepiness and cataplexy) are observed during that phase when mice are highly active. Accordingly, we found only a small female-male effect on the number of PS episodes during the light phase.

Interestingly, when animals were recorded with or without chocolate but in the absence of a mate of the opposite sex, vigilance states were more fragmented in males than females. However, under the best conditions, when recording males and females together and under chocolate treatment, we found no sex-related differences on vigilance states, indicating that males and females may be equally included in studies and preferentially be recorded in the same open space.

Furthermore, we confirmed here the well-known cataplexy eliciting effect of chocolate. We show however that chocolate had more effect on males than females, possibly because males had only a few cataplexies in baseline condition. However, it is remarkable that for both sex, chocolate was approximately 2.5 times less efficient when mice of the opposite sex were present. Such observation should be re-evaluated for confirmation.

We had no difficulties in identifying the 4 EC stages based on cytology. The EC lasts only 4-5 days in mice and some of the stages are relatively short [57]. Therefore, we recorded mice over 3 to 4 cycles to detect all of them. Nevertheless, M could not be detected in one of the females. The shortness of M, often lasting for less than 12 hrs, conducted some authors to exclude it from analysis [7]. In our analysis, we chose to keep it. Nevertheless, we cannot exclude that part of the variability observed in each EC stage is due to transition between stages.

It has been reported in C57Bl6/J mice that sleep duration increases with weight [58]. Here, females were leaner than males although they were of similar age and came from the same litters. Weight differences were highly significant but mild. Accordingly, we found no correlation between weight and cataplexy in baseline (sometimes called spontaneous cataplexy) and under chocolate treatment (food-elicited cataplexy).

Of interest, 8 males were recorded for several nights with females in their close environment. They showed no difference in the number of cataplexy whether 0 to 3 of the female mice present in the environment where in E, a stage where ovulation occurs. It suggests that the hormonal stage of the female does not induce cataplexy in males. Note that females were in the same open-space but not in physical contact with males, which could make a difference.

## **Conclusion**

To conclude, our data indicate that the narcoleptic profile is slightly different in female and male Orex-KO mice, males having more fragmented sleep while female have more cataplexy. In particular, we show that cataplexy is greatly influenced by EC, with a major increase in occurrence during the E stage. How sex hormones modulate the occurrence of cataplexy in mice still needs to be explored. Whether these effects are present in patients with NT1 and due to hormonal changes or the emotional state associated with these hormonal changes would also need to be addressed to get a fuller picture and a better understanding of the physiopathology of NT1.

## **Acknowledgements**

The authors warmly thank Xavier Biolchini and Priscilla Orlando of the CRNL Neurocampus animal facility for animal care. They are grateful to Claire Benetollo (GenCiTy platform, CRNL) for help and advice on vaginal cytology. The authors thank Maxime Grenot for constructive discussion about statistics, and Dr Luc Gentet for its constructive comments and the revision of the English language.

## **Disclosure statements**

Financial disclosure: MV has received a CIFRE doctoral fellowship from Bioprojet Biotech.

Non-financial disclosure: All authors declare no conflicts of interest.

## **Author contributions**

SA, MV and CP conceived and designed the study. SA, MV and CB performed experiments. ALM performed genotyping and helped with the microscopy. SA performed most of the analyses. MV wrote the first draft of the manuscript. SA, MV and CP wrote the paper. All authors reviewed and approved the submitted version.

## REFERENCES

1. Fang J, Fishbein W. Sex differences in paradoxical sleep: influences of estrus cycle and ovariectomy. *Brain Res.* 1996;734(1-2):275-285.
2. Mongrain V, Carrier J, Dumont M. Chronotype and sex effects on sleep architecture and quantitative sleep EEG in healthy young adults. *Sleep.* 2005;28(7):819-827. doi:10.1093/sleep/28.7.819
3. Paul KN, Dugovic C, Turek FW, Laposky AD. Diurnal sex differences in the sleep-wake cycle of mice are dependent on gonadal function. *Sleep.* 2006;29(9):1211-1223. doi:10.1093/sleep/29.9.1211
4. Swift KM, Keus K, Echeverria CG, et al. Sex differences within sleep in gonadally intact rats. *Sleep.* 2020;43(5). doi:10.1093/sleep/zsz289
5. Lee KA, Shaver JF, Giblin EC, Woods NF. Sleep patterns related to menstrual cycle phase and premenstrual affective symptoms. *Sleep.* 1990;13(5):403-409.
6. Parry BL, Mostofi N, LeVeau B, et al. Sleep EEG studies during early and late partial sleep deprivation in premenstrual dysphoric disorder and normal control subjects. *Psychiatry Res.* 1999;85(2):127-143. doi:10.1016/s0165-1781(98)00128-0
7. Koehl M, Battle SE, Turek FW. Sleep in female mice: a strain comparison across the estrous cycle. *Sleep.* 2003;26(3):267-272. doi:10.1093/sleep/26.3.267
8. Baker FC, Lee KA. Menstrual Cycle Effects on Sleep. *Sleep Med Clin.* 2018;13(3):283-294. doi:10.1016/j.jsmc.2018.04.002
9. Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. *Nat Rev Neurol.* 2019;15(9):519-539. doi:10.1038/s41582-019-0226-9
10. Luca G, Haba-Rubio J, Dauvilliers Y, et al. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. *J Sleep Res.* 2013;22(5):482-495. doi:10.1111/jsr.12044
11. Khatami R, Luca G, Baumann CR, et al. The European Narcolepsy Network (EU-NN) database. *J Sleep Res.* 2016;25(3):356-364. doi:10.1111/jsr.12374
12. Longstreth WT, Ton TGN, Koepsell T, Gersuk VH, Hendrickson A, Velde S. Prevalence of narcolepsy in King County, Washington, USA. *Sleep Med.* 2009;10(4):422-426. doi:10.1016/j.sleep.2008.05.009
13. Scheer D, Schwartz SW, Parr M, Zgibor J, Sanchez-Anguiano A, Rajaram L. Prevalence and incidence of narcolepsy in a US health care claims database, 2008-2010. *Sleep.* 2019;42(7):zsz091. doi:10.1093/sleep/zsz091
14. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nat Med.* 2000;6(9):991-997. doi:10.1038/79690
15. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. *Neuron.* 2000;27(3):469-474.

16. Overeem S, van Nues SJ, van der Zande WL, Donjacour CE, van Mierlo P, Lammers GJ. The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. *Sleep Med.* 2011;12(1):12-18. doi:10.1016/j.sleep.2010.05.010
17. Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy—clinical aspects, pathophysiology and management strategy. *Nature Reviews Neurology.* 2014;10(7):386-395. doi:10.1038/nrneurol.2014.97
18. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin Knockout Mice: Molecular Genetics of Sleep Regulation. *Cell.* 1999;98(4):437-451. doi:10.1016/S0092-8674(00)81973-X
19. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. *Arch Neurol.* 2002;59(10):1553-1562.
20. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. *Proc Natl Acad Sci USA.* 2004;101(13):4649-4654. doi:10.1073/pnas.0400590101
21. Hasegawa E, Yanagisawa M, Sakurai T, Mieda M. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. *Journal of Clinical Investigation.* 2014;124(2):604-616. doi:10.1172/JCI71017
22. Mahoney CE, Mochizuki T, Scammell TE. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. *Sleep.* 2020;43(6):zsz302. doi:10.1093/sleep/zsz302
23. Taheri S, Mahmoodi M, Opacka-Juffry J, Ghatei MA, Bloom SR. Distribution and quantification of immunoreactive orexin A in rat tissues. *FEBS Lett.* 1999;457(1):157-161. doi:10.1016/S0014-5793(99)01030-3
24. Jöhren O, Neidert SJ, Kummer M, Dominiak P. Sexually dimorphic expression of prepro-orexin mRNA in the rat hypothalamus. *Peptides.* 2002;23(6):1177-1180. doi:10.1016/S0196-9781(02)00052-9
25. Grafe LA, Cornfeld A, Luz S, Valentino R, Bhatnagar S. Orexins Mediate Sex Differences in the Stress Response and in Cognitive Flexibility. *Biol Psychiatry.* 2017;81(8):683-692. doi:10.1016/j.biopsych.2016.10.013
26. Porkka-Heiskanen T, Kalinchuk A, Alanko L, Huhtaniemi I, Stenberg D. Orexin A and B levels in the hypothalamus of female rats: the effects of the estrous cycle and age. *Eur J Endocrinol.* 2004;150(5):737-742. doi:10.1530/eje.0.1500737
27. Silveyra P, Cataldi NI, Lux-Lantos VA, Libertun C. Role of orexins in the hypothalamic-pituitary-ovarian relationships. *Acta Physiol (Oxf).* 2010;198(3):355-360. doi:10.1111/j.1748-1716.2009.02049.x
28. Dauvilliers Y, Barateau L. Narcolepsy and Other Central Hypersomnias. *Continuum (Minneapolis).* 2017;23(4, Sleep Neurology):989-1004. doi:10.1212/CON.0000000000000492
29. Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. *Neurology.* 2002;58(12):1826-1833. doi:10.1212/wnl.58.12.1826

30. Mattarozzi K, Bellucci C, Campi C, et al. Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy. *Sleep Medicine*. 2008;9(4):425-433. doi:10.1016/j.sleep.2007.05.006
31. Won C, Mahmoudi M, Qin L, Purvis T, Mathur A, Mohsenin V. The impact of gender on timeliness of narcolepsy diagnosis. *J Clin Sleep Med*. 2014;10(1):89-95. doi:10.5664/jcsm.3370
32. Sun Y, Blanco-Centurion C, Zou B, Bendell E, Shiromani PJ, Liu M. Amygdala GABA Neurons Project To vIPAG And mPFC. *IBRO Rep*. 2019;6:132-136. doi:10.1016/j.ibror.2019.03.001
33. Sun Y, Bendell E, Liu M. Amygdala GABAergic neuron activity dynamic during cataplexy of narcolepsy. *Elife*. 2019;8. doi:10.7554/eLife.48311
34. Sun Y, Liu M. Hypothalamic MCH Neuron Activity Dynamics during Cataplexy of Narcolepsy. *eNeuro*. 2020;7(2). doi:10.1523/ENEURO.0017-20.2020
35. Coffey AA, Joyal AA, Yamanaka A, Scammell TE. The Impacts of Age and Sex in a Mouse Model of Childhood Narcolepsy. *Front Neurosci*. 2021;15:644757. doi:10.3389/fnins.2021.644757
36. Sun Y, Tisdale R, Park S, et al. The Development of Sleep/Wake Disruption and Cataplexy as Hypocretin/Orexin Neurons Degenerate in Male vs. Female Orexin/tTA; TetO-DTA Mice. *Sleep*. February 2022:zsac039. doi:10.1093/sleep/zsac039
37. España RA, McCormack SL, Mochizuki T, Scammell TE. Running promotes wakefulness and increases cataplexy in orexin knockout mice. *Sleep*. 2007;30(11):1417-1425.
38. Oishi Y, Williams RH, Agostinelli L, et al. Role of the medial prefrontal cortex in cataplexy. *J Neurosci*. 2013;33(23):9743-9751. doi:10.1523/JNEUROSCI.0499-13.2013
39. Leibiger J, Fendt M. Behavioral analysis of narcoleptic episodes in orexin-deficient mice. *Behav Genet*. 2014;44(2):136-143. doi:10.1007/s10519-013-9634-6
40. Libourel P-A, Corneillie A, Luppi P-H, Chouvet G, Gervasoni D. Unsupervised online classifier in sleep scoring for sleep deprivation studies. *Sleep*. 2015;38(5):815-828. doi:10.5665/sleep.4682
41. Franken P, Malafosse A, Tafti M. Genetic determinants of sleep regulation in inbred mice. *Sleep*. 1999;22(2):155-169.
42. Scammell TE, Willie JT, Guilleminault C, Siegel JM. A Consensus Definition of Cataplexy in Mouse Models of Narcolepsy. *Sleep*. 2009;32(1):111-116.
43. Peyron C, Arthaud S, Villalba M, Fort P. Defining and measuring paradoxical (REM) sleep in animal models of sleep disorders. *Current Opinion in Physiology*. 2020;15:203-209. doi:10.1016/j.cophys.2020.03.008
44. Byers SL, Wiles MV, Dunn SL, Taft RA. Mouse estrous cycle identification tool and images. *PLoS ONE*. 2012;7(4):e35538. doi:10.1371/journal.pone.0035538
45. McLean AC, Valenzuela N, Fai S, Bennett SAL. Performing vaginal lavage, crystal violet staining, and vaginal cytological evaluation for mouse estrous cycle staging identification. *J Vis Exp*. 2012;(67):e4389. doi:10.3791/4389



46. Roman A, Meftah S, Arthaud S, Luppi P-H, Peyron C. The inappropriate occurrence of rapid eye movement sleep in narcolepsy is not due to a defect in homeostatic regulation of rapid eye movement sleep. *Sleep*. 2018;41(6). doi:10.1093/sleep/zsy046
47. Arthaud S, Libourel P-A, Luppi P-H, Peyron C. Insights into paradoxical (REM) sleep homeostatic regulation in mice using an innovative automated sleep deprivation method. *Sleep*. January 2020. doi:10.1093/sleep/zsaa003
48. Schöne C, Burdakov D. Orexin/Hypocretin and Organizing Principles for a Diversity of Wake-Promoting Neurons in the Brain. *Curr Top Behav Neurosci*. 2017;33:51-74. doi:10.1007/7854\_2016\_45
49. Chowdhury S, Hung CJ, Izawa S, et al. Dissociating orexin-dependent and -independent functions of orexin neurons using novel Orexin-Flp knock-in mice. *Elife*. 2019;8:e44927. doi:10.7554/eLife.44927
50. Driver HS, Werth E, Dijk D-J, Borbély AA. The Menstrual Cycle Effects on Sleep. *Sleep Medicine Clinics*. 2008;3(1):1-11. doi:10.1016/j.jsmc.2007.10.003
51. Driver HS, Dijk DJ, Werth E, Biedermann K, Borbély AA. Sleep and the sleep electroencephalogram across the menstrual cycle in young healthy women. *J Clin Endocrinol Metab*. 1996;81(2):728-735. doi:10.1210/jcem.81.2.8636295
52. Baker FC, Driver HS. Circadian rhythms, sleep, and the menstrual cycle. *Sleep Medicine*. 2007;8(6):613-622. doi:10.1016/j.sleep.2006.09.011
53. Colvin GB, Whitmoyer DI, Lisk RD, Walter DO, Sawyer CH. Changes in sleep-wakefulness in female rats during circadian and estrous cycles. *Brain Res*. 1968;7(2):173-181. doi:10.1016/0006-8993(68)90095-4
54. Paul KN, Laposky AD, Turek FW. Reproductive hormone replacement alters sleep in mice. *Neurosci Lett*. 2009;463(3):239-243. doi:10.1016/j.neulet.2009.07.081
55. Schwierin B, Borbély AA, Tobler I. Sleep homeostasis in the female rat during the estrous cycle. *Brain Res*. 1998;811(1-2):96-104. doi:10.1016/s0006-8993(98)00991-3
56. Riehl J, Nishino S, Cederberg R, Dement WC, Mignot E. Development of cataplexy in genetically narcoleptic Dobermans. *Exp Neurol*. 1998;152(2):292-302. doi:10.1006/exnr.1998.6847
57. Ajayi AF, Akhigbe RE. Staging of the estrous cycle and induction of estrus in experimental rodents: an update. *Fertil Res Pract*. 2020;6:5. doi:10.1186/s40738-020-00074-3
58. Guan Z, Vgontzas AN, Bixler EO, Fang J. Sleep is increased by weight gain and decreased by weight loss in mice. *Sleep*. 2008;31(5):627-633. doi:10.1093/sleep/31.5.627

## LEGENDS

### **Video 1. Video-recording associated with EEG/EMG traces illustrating a typical cataplexy in a *Orex-KO* mouse**

On the right side, the horizontal colored bar codes for WK in blue and cataplexy in purple. The EMG signal is the top trace while the EEG recorded from the parietal electrode is the bottom trace. The vertical green line indicates real time of the visualized image.

### **Figure 1. Effects on vigilance states and cataplexy of female and male *Orex-KO* mice of the presence of mice of the opposite sex**

Histograms on the left illustrate the total amount of time (mean  $\pm$  SEM) spent in WK (A), SWS (D), PS (G) and cataplexy (J) over the 12 hrs of the dark phase. Histograms in the middle illustrate the number of WK (B), SWS (E), PS (H) and cataplexy (K) episodes (mean  $\pm$  SEM) while those on the right illustrate the mean episode durations (mean  $\pm$  SEM) for WK (C), SWS (F), PS (I) and cataplexy (L) in the 4 experimental groups, female (F; n=9), females in the presence of males (F (+M); n=8), males (M; n=9) and males in the presence of females (M (+F); n=7). Note that mice of the F group are different mice than those of the F(+M) group, (same for the male population). Statistical tests for independent measures were thus used. Each dot represents one animal, female (purple) and male (blue). \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

### **Figure 2. Quantification of vigilance states and cataplexy under chocolate treatment and in the presence of a mouse of the opposite sex in female versus male *Orex-KO* mice**

Histograms on the left illustrate the total amount of time (mean  $\pm$  SEM) spent in WK (A), SWS (D), PS (G) and cataplexy (J) of 10 females (+M+C) and 8 males (+M+C) during the dark phase. Histograms in the middle illustrate the number of WK (B), SWS (E), PS (H) and cataplexy (K) episodes (mean  $\pm$  SEM) while those on the right illustrate the mean episode durations (mean  $\pm$  SEM) for WK (C), SWS (F), PS (I) and cataplexy (L). Each dot represents one animal. \*  $p < 0.05$ .

### **Figure 3. Illustration of cataplexy in Orex-KO female mice across the EC**

Box plots report median (min;max) of the total amount (A), the number of episodes (C), and the mean episode durations (E) of cataplexy (A, C, E respectively) in P, E, M and D of female mice (n=10). Each purple dot represents the median value for one female animal. Females and males (n=8) were recorded in the presence of mice of the opposite sex and under chocolate treatment. Note that values obtained from males are also illustrated in Figure 2 but are reported here again to illustrate which phases of the EC in females are different compared to males. B, D and F panels illustrate the normalized values corresponding to A, C and E respectively for cataplexy in females across the EC. Dotted grey lines in B, D, F trace cataplexy across the EC for each given female. Thick black horizontal lines represent the mean values ( $\pm$  SEM). \*  $p < 0.05$ ; \*\*  $p < 0.01$ . P, proestrus; E, estrus; EC, estrous cycle; M, metestrus; D, diestrus.

**Table 1. Vigilance states and cataplexy quantification of female and male mice recorded over 24 hrs of baseline**


The total amount, number of episodes and mean episodes duration of vigilance states and cataplexy are represented by the mean  $\pm$  SEM in females (n=9) and males (n=9). Data are extracted from the experiment 1 when mice were recorded in absence of chocolate and of animals of the opposite sex.

Statistical tests: unpaired t-test or Mann-Whitney test were used depending on whether data followed a normal distribution or not, respectively; ns: non-significant; \* p<0.05; \*\* p<0.01.


**Table 2. Quantification of vigilance states and cataplexy during the 12 hrs of dark phase in female and male Orex-KO mice having access, or not, to chocolate**

The total amount, number of episodes and mean episodes duration of vigilance states and cataplexy are reported as mean  $\pm$  SEM in 8 female and 9 male mice with or without chocolate. These animals were recorded in absence of mice of the opposite sex. Statistical tests: paired t-test or Wilcoxon test to compare females vs. females with chocolate and males vs. males with chocolate; unpaired t-test or Mann-Whitney test to compare males with chocolate vs. females with chocolate; ns: non-significant; \* p<0.05; \*\* p<0.01; \*\*\*p<0.001.


**FIGURE 1**



**FIGURE 2**



**FIGURE 3**



**TABLE 1**

	Wakefulness			Slow-wave sleep			Paradoxical sleep			Cataplexy		
	Total amount (min)	Number of episodes	Mean episodes duration (sec)	Total amount (min)	Number of episodes	Mean episodes duration (sec)	Total amount (min)	Number of episodes	Mean episodes duration (sec)	Total amount (min)	Number of episodes	Mean episodes duration (sec)
<b>Females (n=9)</b>	<b>741.78</b> +/- 28.0	<b>440.33</b> +/- 20.5	<b>103.08</b> +/- 6.9	<b>586.70</b> +/- 29.6	<b>418.44</b> +/- 24.6	<b>85.69</b> +/- 4.8	<b>96.83</b> +/- 4.1	<b>135.89</b> +/- 7.4	<b>43.25</b> +/- 1.9	<b>14.85</b> +/- 4.2	<b>21.67</b> +/- 6.5	<b>36.61</b> +/- 5.7
<b>Males (n=9)</b>	<b>742.44</b> +/- 15.0	<b>496.44</b> +/- 24.9	<b>91.13</b> +/- 3.8	<b>584.69</b> +/- 16.4	<b>491.33</b> +/- 25.1	<b>73.49</b> +/- 5.4	<b>110.08</b> +/- 2.4	<b>178.22</b> +/- 6.5	<b>37.42</b> +/- 1.1	<b>2.57</b> +/- 1.6	<b>5.56</b> +/- 2.0	<b>17.51</b> +/- 3.9
<b>Test</b>	Unpaired t test	Unpaired t test	Unpaired t test	Unpaired t test	Unpaired t test	Unpaired t test	Mann-Whitney	Mann-Whitney	Unpaired t test	Mann-Whitney	Mann-Whitney	Mann-Whitney
<b>t, df values or U value</b>	t=0.021 df=16	t=1.738 df=16	t=1.528 df=16	t=0.059 df=16	t=2.074 df=16	t=1.676 df=16	U=16	U=8	t=2.617 df=16	U=17	U=20.5	U=13
<b>p value</b>	<b>0.9836</b> ns	<b>0.1015</b> ns	<b>0.1461</b> ns	<b>0.9532</b> ns	<b>0.0546</b> ns	<b>0.1131</b> ns	<b>0.0315</b> *	<b>0.0025</b> **	<b>0.0487</b> *	<b>0.0375</b> *	<b>0.0801</b> ns	<b>0.0142</b> *



## TABLE 2

	Wakefulness			Slow-wave sleep			Paradoxical sleep			Cataplexy		
	Total amount (min)	Number of episodes	Mean episodes duration (sec)	Total amount (min)	Number of episodes	Mean episodes duration (sec)	Total amount (min)	Number of episodes	Mean episodes duration (sec)	Total amount (min)	Number of episodes	Mean episodes duration (sec)
Females (n=8)	484.40 +/- 21.0	175.40 +/- 11.4	173.50 +/- 19.4	191.60 +/- 21.8	155.00 +/- 16.4	74.85 +/- 4.1	30.64 +/- 3.4	40.00 +/- 3.9	45.69 +/- 1.9	13.22 +/- 4.3	20.25 +/- 7.0	34.81 +/- 6.2
Females with CHOCO (n=8)	556.80 +/- 12.7	172.30 +/- 10.6	200.2 +/- 14.6	88.00 +/- 11.8	90.75 +/- 12.5	58.88 +/- 5.3	23.91 +/- 3.8	32.63 +/- 6.1	45.33 +/- 4.1	51.25 +/- 7.9	80.88 +/- 14.1	38.97 +/- 1.7
Males (n=9)	473.82 +/- 8.3	216.89 +/- 13.5	134.76 +/- 7.7	207.03 +/- 8.3	211.44 +/- 13.9	60.77 +/- 4.7	36.50 +/- 1.3	63.67 +/- 3.9	35.56 +/- 2.8	2.53 +/- 1.6	5.44 +/- 1.9	17.63 +/- 4.0
Males with CHOCO (n=9)	509.91 +/- 17.4	228.11 +/- 14.9	140.50 +/- 14.8	148.79 +/- 18.8	190.67 +/- 21.4	46.87 +/- 3.4	37.69 +/- 5.8	63.44 +/- 9.5	37.69 +/- 5.8	23.50 +/- 8.8	37.33 +/- 11.1	31.50 +/- 4.1
Females vs. Females with CHOCO	Paired t test t=3.030 df=7 p=0.0191 *	Paired t test t=0.192 df=7 p=0.8531 ns	Paired t test t=1.011 df=7 p=0.3458 ns	Paired t test t=5.267 df=7 p=0.0012 **	Paired t test t=4.245 df=7 p=0.0038 **	Paired t test t=3.412 df=7 p=0.0113 *	Paired t test t=1.751 df=7 p=0.1234 ns	Paired t test t=1.234 df=7 p=0.2570 ns	Paired t test t=0.078 df=7 p=0.9402 ns	Paired t test t=7.430 df=7 p=0.0001 ***	Paired t test t=6.674 df=7 p=0.0003 ***	Paired t test t=0.666 df=7 p=0.5269 ns
Males vs. Males with CHOCO	Wilcoxon test W=39 p=0.0195 *	Paired t test t=0.546 df=8 p=0.6003 ns	Wilcoxon test W=-7 p=0.7344 ns	Paired t test t=3.262 df=8 p=0.0115 *	Wilcoxon test W=3 p=0.9102 ns	Paired t test t=4.731 df=8 p=0.0015 **	Paired t test t=0.188 df=8 p=0.8558 ns	Paired t test t=0.029 df=8 p=0.9779 ns	Wilcoxon test W=11 p=0.5703 ns	Wilcoxon test W=45 p=0.0039 **	Wilcoxon test W=45 p=0.0039 **	Wilcoxon test W=45 p=0.0039 **
Females with CHOCO vs. Males with CHOCO	Mann-Whitney test U=15 p=0.0464 *	Unpaired t test t=3.102 df=15 p=0.0073 **	Mann-Whitney test U=9 p=0.0079 **	Unpaired t test t=2.798 df=15 p=0.0135 *	Mann-Whitney test U=7 p=0.0037 **	Unpaired t test t=1.988 df=15 p=0.0654 ns	Unpaired t test t=2.029 df=15 p=0.0606 ns	Unpaired t test t=2.764 df=15 p=0.0145 *	Mann-Whitney test U=19 p=0.1139 ns	Unpaired t test t=2.407 df=15 p=0.0294 *	Unpaired t test t=2.513 df=15 p=0.0239 *	Unpaired t test t=1.704 df=15 p=0.1089 ns